<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Glaxo Cuts Prices On AIDS Drugs For Poor Nations</title>
	<atom:link href="http://www.pharmalot.com/2008/02/glaxo-cuts-prices-on-aids-drugs-for-poor-nations/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2008/02/glaxo-cuts-prices-on-aids-drugs-for-poor-nations/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 21:09:47 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: Ray-Anne Carr</title>
		<link>http://www.pharmalot.com/2008/02/glaxo-cuts-prices-on-aids-drugs-for-poor-nations/#comment-171154</link>
		<dc:creator>Ray-Anne Carr</dc:creator>
		<pubDate>Thu, 21 Feb 2008 13:02:41 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/02/glaxo-cuts-prices-on-aids-drugs-for-poor-nations/#comment-171154</guid>
		<description>I would be interested to see the source countries of some of these starting materials and the risk assessment carried out on the long term viability of the strategy. 
Of course the true impact of this generous decision will only be seen by patients when the local purchasing and distribution network matches theoretical policy with on the ground medical treatment.</description>
		<content:encoded><![CDATA[<p>I would be interested to see the source countries of some of these starting materials and the risk assessment carried out on the long term viability of the strategy.<br />
Of course the true impact of this generous decision will only be seen by patients when the local purchasing and distribution network matches theoretical policy with on the ground medical treatment.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Bob Freeman</title>
		<link>http://www.pharmalot.com/2008/02/glaxo-cuts-prices-on-aids-drugs-for-poor-nations/#comment-169700</link>
		<dc:creator>Bob Freeman</dc:creator>
		<pubDate>Wed, 20 Feb 2008 16:08:20 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/02/glaxo-cuts-prices-on-aids-drugs-for-poor-nations/#comment-169700</guid>
		<description>Agree, Truthman. Certainly nothing new.</description>
		<content:encoded><![CDATA[<p>Agree, Truthman. Certainly nothing new.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: truthman</title>
		<link>http://www.pharmalot.com/2008/02/glaxo-cuts-prices-on-aids-drugs-for-poor-nations/#comment-169690</link>
		<dc:creator>truthman</dc:creator>
		<pubDate>Wed, 20 Feb 2008 16:02:33 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/02/glaxo-cuts-prices-on-aids-drugs-for-poor-nations/#comment-169690</guid>
		<description>How kind of Glaxo...
Good PR Move..
That's about all it amounts to...</description>
		<content:encoded><![CDATA[<p>How kind of Glaxo&#8230;<br />
Good PR Move..<br />
That&#8217;s about all it amounts to&#8230;</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Bob Freeman</title>
		<link>http://www.pharmalot.com/2008/02/glaxo-cuts-prices-on-aids-drugs-for-poor-nations/#comment-169683</link>
		<dc:creator>Bob Freeman</dc:creator>
		<pubDate>Wed, 20 Feb 2008 15:48:34 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/02/glaxo-cuts-prices-on-aids-drugs-for-poor-nations/#comment-169683</guid>
		<description>Interesting piece--I don't think the reduction in manufacturing/distribution costs is the underlying reason for the pricing decision.  Rather, I see this as a way to maintain control of the products per se and a way to avoid compulsory licensing by making it less attractive for generic suppliers to enter the market.  (I'm not all that convinced either that price concessions are sustainable in the long-term.)

I am more impressed with Roche's corporate decision to forgo patent registrations in these countries as well as their commitment to building a manufacturing and distribution networks in those countries.</description>
		<content:encoded><![CDATA[<p>Interesting piece&#8211;I don&#8217;t think the reduction in manufacturing/distribution costs is the underlying reason for the pricing decision.  Rather, I see this as a way to maintain control of the products per se and a way to avoid compulsory licensing by making it less attractive for generic suppliers to enter the market.  (I&#8217;m not all that convinced either that price concessions are sustainable in the long-term.)</p>
<p>I am more impressed with Roche&#8217;s corporate decision to forgo patent registrations in these countries as well as their commitment to building a manufacturing and distribution networks in those countries.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.152 seconds -->

